NCT04925583Active, not recruitingPhase 1
Magnetic Resonance Guided Adaptive Stereotactic Body Radiotherapy for Lung Tumors in Ultracentral Location
Source: ClinicalTrials.gov · Last updated 2 Apr 2026
Brief summary (registry, in English)
MAGELLAN is a phase-I dose escalation trial that aims to identify the maximum tolerated dose (MTD) of MR-guided SBRT of ultracentral lung Tumors (primary objective). Thus, a maximum of 38 patients with ultracentral lung tumors (overlap of the planning target volume with the proximal bronchial tree and/or esophagus) will receive MR-guided SBRT including gated dose delivery and daily plan adaptation on a 0.35 MR-linac System. Dose levels are as follows: * 0 (de-escalation): 10 x 5.0Gy * 1 (start): 10 x 5.5Gy * 2: 10 x 6.0Gy * 3: 10 x 6.5Gy Dose escalation is performed according to a time-to-event continual reassessment method (TITE-CRM) with backup element. Patients are observed individually for 12 months to detect potential dose limiting toxicity (DLT = primary endpoint) and for a total of 24 months to detect potential tumor relapse.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (estimated)
- First submitted
- 18 May 2021
- Start date
- 1 Nov 2021
- Primary completion date
- 1 Nov 2030
- Lead sponsor
- University Hospital Heidelberg
- Diseases
- Lung cancer
- NCT number
- NCT04925583
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 38
- From 1 Nov 2021 to the primary completion date, 1 Nov 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- previous radiotherapy of the lung and mediastinum, if previous and current target volumes overlap
- patients who have not yet recovered from acute toxicities of prior therapies
- (planned) treatment with vascular endothelial growth factor (VEGF) inhibitors, e.g. Bevacizumab, within the time interval 2 weeks before and 2 weeks after SBRT
- contraindications against performing MRI scans (pacemakers, other implants making MRI impossible)
Other
- refusal of the patients to take part in the study
- pregnant or lactating women
- participation in another competing clinical study or observation period of competing trials
Who the study is looking for
- ultracentral location of the lung tumor, which is defined as an expected contact or overlap of the planning target volume with the proximal bronchial tree or esophagus at the time of consultation
- indication for SBRT of the ultracentral pulmonary tumor
- maximum diameter of the ultracentral pulmonary tumor \< 5cm
- age \> 18 years of age
- Karnofsky Performance Score \> 70% (ECOG Score 0 - 2)
- ability to lie still on the MR-linac table for at least one hour
- ability to hold one's breath for more than 20 seconds
- successful completion of MRgRT simulation
- for women with childbearing potential, adequate contraception.
- ability of subject to understand character and individual consequences of the clinical trial
- written informed consent (must be available before enrolment in the trial)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital of Heidelberg, Radiation Oncology Coordinator of this site? Confirm its status | Heidelberg | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.